Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic
cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated …

Importance Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell
transplantation (allo-HCT) in myelodysplastic syndrome even if they are older. However …

The guidelines for classification, prognostication, and response assessment of
myelodysplastic syndromes/neo-plasms (MDS) have all recently been updated. In this report …

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem
cell neoplasms primarily affecting older persons, associated with dysplastic changes of bone …

Myelodysplastic syndromes (MDS) are a diverse group of hematological malignancies
distinguished by a combination of dysplasia in the bone marrow, cytopenias and the risk of …

Accurate risk prognostication is central to the management of myelodysplastic syndromes,
given the widely heterogeneous clinical outcomes of these bone marrow failure disorders …

The guidelines for classification, prognostication, and response assessment of
myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable treatment
option for adolescent and young adult (AYA) patients with myelodysplastic syndrome (MDS) …

In patients with myelodysplastic syndrome (MDS), higher revised International Prognostic
Scoring System (IPSS-R) scores at transplant are associated with worse transplant outcome …